Dare Bioscience, Inc.
DARE
Rank in Stocks
#28693
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic... Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Share Price
$0.68
Last synced: 2026-11-09
Market Cap
$10.19M
Change (1 day)
6.42%
Change (1 year)
-64.95%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Dare Bioscience, Inc. (DARE)
Category
Healthcare
Operating Margin for Dare Bioscience, Inc. (DARE)
Operating Margin as of November 2026 TTM: -813.38%
According to Dare Bioscience, Inc.'s latest financial reports, its current operating margin (TTM) is -813.38%. At the end of 2025 the company had an operating margin of -1,315.51%.
Operating Margin history for Dare Bioscience, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -813.38% | -38.17% |
| 2025 | -1,315.51% | -99.45% |
| 2024 | -239,692.20% | 21,652.82% |
| 2023 | -1,101.89% | 251.09% |
| 2022 | -313.85% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -4,850.39% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -25,348.75% | -90.41% |
| 2013 | -264,333.33% | 7,557.40% |
| 2012 | -3,452.00% | -44.23% |
| 2011 | -6,189.51% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Dare Bioscience, Inc.'s operating margin
What is Dare Bioscience, Inc.'s operating margin?
Dare Bioscience, Inc.'s operating margin is -813.38%, as of Nov 2026.
What was Dare Bioscience, Inc.'s operating margin in 2025?
In 2025, Dare Bioscience, Inc.'s operating margin was -1,315.51%, compared with -239,692.20% in 2024.
How has Dare Bioscience, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Dare Bioscience, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2024 (-239,692.20%).
How does Dare Bioscience, Inc.'s operating margin compare with similar companies?
Dare Bioscience, Inc.'s operating margin (-813.38%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.